C62-M4 / University of North Carolina-Chapel Hill, National Institute of Allergy and Infectious Diseases - LARVOL DELTA

AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine | Active, not recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease

AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: University of Oxford

New P2 trial • Human Immunodeficiency Virus • Infectious Disease

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: University of North Carolina, Chapel Hill | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: University of North Carolina, Chapel Hill | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Dec 2025 ➔ Feb 2025 | Trial primary completion date: Sep 2025 ➔ Sep 2024

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

ACHIEV: Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for the Induction of HIV Remission (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

New P1 trial • Human Immunodeficiency Virus • Infectious Disease

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial primary completion date: Dec 2023 ➔ May 2024

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells (ASH 2022) - "NEO-TRA1 exhibits potent expansion of Treg populations within primary human samples and in humanized mouse models. The observed profile of STAT5 phosphorylation demonstrates selective activation of Tregs over other lymphocyte populations. NEO-TRA1 is the first Treg agonist based on de novo protein design."

Graft versus Host Disease • Immunology • Inflammation • CD4 • CD8 • FCGR2A • FCGR2B • FOXP3 • IL2 • IL2RA • IL7R • STAT5

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4